Lyophilized recombinant human brain natriuretic peptide for chronic heart failure: Effects on cardiac function and inflammation

Table 1 Comparison of the clinical outcomes between the two study groups, n (%)

Group	Visible effect	Effective	Invalid	Total validity
Control group (n = 51)	15 (29.41)	19 (37.25)	17 (33.33)	34 (66.67)
Observation group (n = 51)	25 (49.02)	20 (39.22)	6 (11.76)	45 (88.24)
χ2 value				6.793
P value				0.009

Table 2 Comparison of the inflammatory response and myocardial injury indicators between the two study groups (mean ± SD)

Group	hs-CRP (mg/L)		NT-proBNP (pg/mL)		cTnI (mg/L)
	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
Control group (n = 51)	15.23 ± 1.57	8.78 ± 0.94a	1548.67 ± 255.81	953.18 ± 115.55a	0.24 ± 0.07	0.18 ± 0.03a
Observation group (n = 51)	15.32 ± 1.41	4.11 ± 0.65a	1564.74 ± 256.92	764.85 ± 86.74a	0.23 ± 0.05	0.04 ± 0.01a
t value	0.305	29.182	0.317	9.309	0.830	31.616
P value	0.761	< 0.001	0.752	< 0.001	0.408	< 0.001

^aP < 0.05 vs pretreatment.

hs-CRP: High sensitivity C-reactive protein; BNP: Brain natriuretic peptide; cTnI: Troponin I.

Table 3 Comparison of the cardiac functions between the two study groups (mean ± SD)

Group	LVEF (%)		SV (mL)
	Before treatment	After treatment	Before treatment	After treatment
Control group (n = 51)	31.43 ± 4.54	51.71 ± 7.98a	44.28 ± 6.52	52.85 ± 6.58a
Observation group (n = 51)	30.32 ± 4.45	58.13 ± 7.62a	43.65 ± 6.47	76.47 ± 8.24a
t value	1.247	4.155	0.490	15.996
P value	0.215	< 0.001	0.625	< 0.001

^aP < 0.05 vs pretreatment.

LVEF: Left ventricular ejection fraction; SV: Stroke volume.

Table 4 Comparison of the quality of life between the two groups (mean ± SD, score)

Group	Physical strength		Emotions		Society		Economy
	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
Control group (n = 51)	34.48 ± 3.56	22.72 ± 2.93a	17.42 ± 2.14	7.12 ± 1.81a	12.23 ± 2.54	7.84 ± 1.52a	10.25 ± 1.23	6.52 ± 1.28a
Observation group (n = 51)	34.35 ± 3.41	17.15 ± 2.64a	17.63 ± 2.25	5.83 ± 1.24a	12.62 ± 2.45	5.41 ± 1.24a	10.36 ± 1.25	4.25 ± 0.57a
t value	0.188	10.086	0.483	4.199	0.789	8.847	0.448	11.570
P value	0.851	< 0.001	0.630	< 0.001	0.432	< 0.001	0.655	< 0.001

^aP < 0.05 vs pretreatment.

Table 5 Comparison of the adverse reactions between the two study groups, n (%)

Group	Headaches	Nausea	Low blood pressure	Total occurrence of adverse reactions
Control group (n = 51)	1 (1.96)	1 (1.96)	1 (1.96)	3 (5.88)
Observation group (n = 51)	0 (0.00)	1 (1.96)	1 (1.96)	2 (3.92)
χ2 value				0.000
P value				1.000